Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Humalog Therapies Right
  4. HUMALOG® (insulin lispro) 100 units/mL: Biosimilarity to Admelog® (insulin lispro) 100 units/mL
Search Humalog (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Humalog® Therapies

Humalog® U-100 (insulin lispro injection)

100 units/mL
Full Prescribing Information

Humalog® U-200 (insulin lispro injection)

200 units/mL
Full Prescribing Information

Humalog® MIX50/50™ (50% insulin lispro protamine suspension 50% insulin lispro injection [rDNA origin])

100 units/mL
Full Prescribing Information

Humalog® MIX75/25™ (75% insulin lispro protamine suspension 25% insulin lispro injection [rDNA origin])

100 units/mL
Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

HUMALOG® (insulin lispro) 100 units/mL: Biosimilarity to Admelog® (insulin lispro) 100 units/mL

Admelog (insulin lispro) is not considered biosimilar to Humalog (insulin lispro) in the United States.

US_cFAQ_LIS702_CONSUMER_ADMELOG_BIOSIMILARITY
US_cFAQ_LIS702_CONSUMER_ADMELOG_BIOSIMILARITY
en-US

Detailed Information

Sanofi-Aventis in 2017, received FDA approval for Admelog® (insulin lispro injection) 100 units/mL via an abbreviated pathway as a follow-on biologic. The Admelog new drug application allowed the FDA to consider the safety and efficacy of Humalog® (insulin lispro injection) 100 units/mL as the relied upon listed drug and two phase 2 clinical trials specific to Admelog. In March 2020, all insulins were transitioned from drugs to biologics and due to regulatory definitional differences, Admelog is not considered a biosimilar in the United States.

Lilly has not investigated Admelog. The best source of information for any product is its manufacturer. Therefore, please refer to Sanofi-Aventis for questions specific to Admelog.

It is important to talk to your health care provider if you are unsure about your current prescribed dose of insulin. He/she is in the best position to discuss your insulin dose as he/she has access to your medical records. If your health care provider has questions or needs additional information about Humalog, please have him/her contact Lilly at 1-800-Lilly-Rx (1-800-545-5979).

Glossary

FDA = Food and Drug Administration

Lilly = Eli Lilly and Company

Date of Last Review: July 29, 2020

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly